Genetic Mutation Analysis in Small Cell Lung Cancer by a Novel NGS-Based Targeted Resequencing Gene Panel and Relation with Clinical Features
Table 1
Clinical characteristics of SCLC patients.
Parameters
Clinical values
Stage I
Stages II + III
value
Age (years old)
65 (49, 81)
67 (51, 81)
63 (49, 81)
0.2506
Sex (male/female)
24/8
12/4
12/4
0.9999
CYFRA21-1 (ng/ml)
4.94 (1.24, 19.53)
3.41 (1.24, 19.53)
3.07 (2.04, 4.43)
0.5033
CEA (ng/ml)
4.33 (0.83, 18.37)
2.97 (0.83, 16.59)
2.52 (1.37, 18.37)
0.9786
NSE (ng/ml)
14.37 (1.83, 34.00)
10.74 (1.83, 20.26)
15.60 (11.38, 34.00)
SCCA (ng/ml)
0.97 (0.20, 3.08)
0.88 (0.20, 1.83)
0.86 (0.21, 3.08)
0.9742
Reported are median and range, except for sex is total individuals. values for age, CYFRA21-1, CEA, NSE, and SCCA were generated by Wilcoxon rank sum test; value for sex was generated by Fisher’s exact test.
